Methods: Twenty-one submitted cases are reviewed and summarized, with emphasis on key diagnostic or biologic points, and supplemented with relevant literature citations.
Results: Early T-cell precursor (ETP)-ALL represented about one-third of all cases submitted. It is important to recognize ETP-ALL, because these patients have a poor prognosis if treated with standard therapy. A consensus immunophenotype has been developed to aid in the recognition of these cases. Other cases submitted illustrated rare entities, including two cases of Philadelphia chromosome-positive T-ALL, two cases of T-ALL associated with MYC translocations, and single cases illustrating various diseases. A subset of cases submitted illustrated issues related to differential diagnosis of T-ALL/T-LBL.

Conclusions: In view of the growing importance of molecular genetic analysis in the diagnosis and prognosis of T-ALL/T-LBL, it is important for pathologists to keep
T-acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) are neoplasms of immature T-cell precursors or lymphoblasts. T-ALL is less common than B-acute lymphoblastic leukemia (B-ALL) and accounts for approximately 15% of all childhood acute lymphoblastic leukemia (ALL) cases. 1, 2 These neoplasms tend to occur in older adolescents, with a male predominance. These tumors also arise in adults; T-ALL represents around 25% of all adult cases of ALL. In contrast with T-ALL, T-LBL is far more common than B-lymphoblastic lymphoma; 85% to 90% of all cases of T-LBL are of T-cell lineage. 1, 2 T-ALL/T-LBL is characterized by a proliferation of lymphoblasts that can show a spectrum of cytologic features. The designations L1 and L2 have no clinical significance but are helpful for describing this spectrum. L1-type blasts are small blasts with a high nucleus/cytoplasm ratio and small nucleoli. L2 blasts are larger blasts with prominent nucleoli and more abundant cytoplasm. Cytoplasmic vacuoles can Upon completion of this activity you will be able to:
•
discuss the clinical features of T-acute lymphoblastic leukemia/Tlymphoblastic lymphoma (T-ALL/T-LBL). • describe the common molecular genetic and immunophenotypic features of T-ALL/T-LBL. • list and compare various entities in the differential diagnosis of T-lymphoblastic proliferations.
The ASCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ASCP designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit ™ per article. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module.
The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose.
Exam is located at www.ascp.org/ajcpcme.
DOI: 10.1309/AJCPMF03LVSBLHPJ
© American Society for Clinical Pathology be seen in lymphoblasts in a subset of cases. The diagnosis of T-ALL/T-LBL further relies on immunophenotypic demonstration of T-cell lineage, with the most specific T-cell marker being CD3. Application of conventional cytogenetic analysis and high-throughput molecular methods to the study of T-ALL/T-LBL has shown that T-ALL/T-LBL is highly heterogeneous. The results of these methods also have informed clinical risk stratification, prognosis, and treatment.
Patients with T-ALL/T-LBL have clinically aggressive disease. [3] [4] [5] These patients often have high-risk clinical features such as older patient age, high leukocyte count, or other indications of high tumor burden, and central nervous system involvement is not uncommon. In general, patients with T-ALL/T-LBL have a poorer prognosis than similar patients with B-ALL/T-LBL. However, intensified chemotherapy protocols have increased the cure rate to approximately 75% in pediatric patients and 50% in adults.
What Is the Definition of T-Lymphoblastic Leukemia/Lymphoma?
As stated in the current World Health Organization classification, T-lymphoblastic leukemia/lymphoma is a neoplasm of lymphoblasts committed to T-cell lineage involving bone marrow (BM), blood, or presenting as a tissue-based mass involving the thymus, lymph nodes, or extranodal sites. 2 By convention, the designation of T-LBL is used when the neoplasm is confined to a mass lesion without or with only minimal blood or BM involvement. The designation of ALL is best used when there is extensive blood and BM disease.
What Is the Immunophenotype of T-ALL/T-LBL?
The earliest marker of T-cell lineage is CD7, but the most specific marker is CD3. Cytoplasmic CD3 is expressed earlier in T-cell differentiation and therefore is more helpful, but surface CD3 is more specific. Cases of T-ALL/T-LBL represent neoplasms that appear to be frozen in place in differentiation, although admittedly this concept is too simplistic. In an attempt to place T-ALL/T-LBL in the context of normal T-cell development, the European Group for the Immunological Characterization of Leukemias proposed classification into four groups: pro-T (CD7+), pre-T (CD2+ and/or CD5+ and/or CD8+), cortical T (CD1a+), and mature T (surface CD3+, CD1a-) ❚Table 1❚. 6 Although this approach is a useful construct in which to conceptualize T-ALL/T-LBL and guide immunophenotypic characterization in terms of lineage assignment and diagnostic flow cytometry panel construction, this approach has limited utility in understanding the genetic basis and clinical heterogeneity of T-ALL.
What Are the Common Cytogenetic Abnormalities in T-ALL/T-LBL?
One recurring theme is the presence of translocations involving transcription factor oncogenes, often aberrantly overexpressed by being brought under the control of enhancers of the T-cell receptor genes. 7 Major categories of transcription factor oncogenes include basic helix-loophelix genes, LIM-only domain (LMO) genes, homeobox (HOX) genes, and proto-oncogenes such as MYC and MYB ❚Table 2❚. 7 
What Are the Molecular Abnormalities in T-ALL/T-LBL?
In addition to these structural abnormalities, other key molecular alterations have been identified that can be broadly grouped into key pathways or categories. These groups include the NOTCH pathway, cell cycle abnormalities, cell growth transcription factors, tumor suppressors, signal transduction, and chromatin remodeling ❚Table 3❚. 7 Of these, NOTCH1 is of particular interest since this pathway is activated frequently in T-ALL/T-LBL. NOTCH1 is a transmembrane receptor expressed on T-cell progenitors. Interaction with its ligand in the thymic microenvironment results in proteolytic cleavage events, mediated by ADAM10/ADAM17 and g secretase, and release of the NOTCH1 intracellular domain subunit (NICD1) that translocates to the nucleus and activates a transcriptional program whose targets include MYC, DTX1, and HES1. 8 Translocations involving the NOTCH1 locus have been described, but they are rare. Instead, activating mutations in NOTCH1 or inactivating mutations of its negative regulator (FBXW7) occur in approximately 60% of T-ALL cases. [7] [8] [9] [10] Targeting the NOTCH pathway is an active area of therapeutic research.
❚Table 1❚ Immunophenotypic Subtypes of T-ALL/T-LBL a
Gene expression profiling (GEP), arguably a reflection of the biologic integration of these genetic alterations, has been performed in T-ALL cases. As in other systems, patterns of gene expression (or signatures) were identified that have helped define an important subtype of T-ALL. 11, 12 Ferrando and coworkers 12 identified aberrant expression of HOX11/ TLX1, TAL1, LYL1, LMO1, and LMO2 in the absence of chromosomal abnormalities and identified signatures indicating maturation arrest at known stages of normal thymic development. LYL1 was associated with a pro-T-cell stage, TLX1 with the early cortical thymocyte stage, and TAL1 with the late cortical thymocyte stage. TLX3 was also identified as a pathway important in leukemogenesis. These signatures have been shown to be clinically relevant. Tumors that have a LYL1, TAL1, or TLX3 signature are associated with a poorer prognosis, whereas TLX1 activation is associated with a favorable prognosis. 12 This association with stage of maturation determined by GEP and outcome later proved to have an immunophenotypic correlate relevant to diagnosis with the subsequent discovery of early T-precursor (ETP)-ALL (discussed below). 
What Are the Features of ETP-ALL?
ETP-ALL was the most common case type submitted to the session ❚Table 4❚. Case 440 is illustrative. This 58-year-old man had weakness and fatigue, and a CBC showed anemia and neutropenia with many blasts. BM examination showed diffuse effacement with 83% blasts ❚Image 1❚. Immunophenotyping showed expression of CD2, cytoplasmic CD3, CD7, CD13, CD15, CD34, CD117, and TdT, and the blasts were negative for CD1a, CD4, CD5, and CD8. The review panel also found other submitted cases as acceptable as ETP-ALL, including one case with a classic immunophenotype (case 97) and others with immunophenotypic variations. These variations included CD56 expression (cases 243 and 325), low-level CD19 expression (case 266), and low-level CD79a expression (case 354). These immunophenotypic variations highlight the fact that boundaries of an acceptable immunophenotype are yet to be defined in ETP-ALL. This is perhaps not surprising because we are using immunophenotype as a surrogate to identify a biologic entity that was defined by GEP.
ETP-ALL was initially recognized by GEP studies that identified a subset of cases that had high expression of LYL1 and LMO2. 12 These neoplasms were shown to have a profile very similar to normal or stem cell-like thymocyte T-cell precursors, leading to its name, ETP-ALL. Patients with ETP-ALL were shown to have a much poorer outcome than other patients with T-ALL, with a 10-year overall survival of 19% for ETP-ALL vs 84% for patients with non-ETP-ALL. 13 Other studies at many centers have confirmed the poor prognosis of patients with ETP-ALL, and this disease represents between 5% and 15% of all cases of T-ALL.
Immunophenotypic analysis has defined a correlative immunophenotype helpful for recognizing cases of ETP-ALL. The blasts of ETP-ALL are usually negative for CD1a and CD8, weakly express CD5 (<75% cells positive), and express one or more myeloid or stem cell markers by at least 25% of blasts, including CD11b, CD13, CD33, CD34, CD65, CD117, or HLA-DR. 13 At the genetic level, cases of ETP-ALL seem to have overlapping features of T-ALL and acute myeloid leukemia. Genetic abnormalities common in T-ALL, such as NOTCH1 mutations and deletions of chromosome 9/CDKN2A, occur much less frequently in ETP-ALL. Instead, deletions involving chromosome loci 5q, 11q, and 13q are common. In sequencing studies, ETP-ALL cases have been shown to have a high frequency of activating mutations involving RAS signaling (eg, NRAS, KRAS, BRAF) and cytokine receptor pathways (eg, IL7R, JAK1, JAK3), as well as inactivating mutations in transcription factors involved in the development of hematopoiesis (eg, ETV6, GATA3, RUNX1, IKZF1) and histone modification (eg, EZH2 and many others). 14, 15 It is important to remember that ETP-ALL is part of a larger group of so-called early T-ALL cases, but ETP-ALL cases are not synonymous with early T-ALL cases. Early T-ALL cases are a biologically heterogeneous group with variable prognosis, although some subsets of patients in this group appear to also have a poor prognosis.
Does Philadelphia ChromosomePositive T-ALL Exist?
Although previously controversial and rare, it is now accepted that Philadelphia chromosome-positive (Ph+) T-ALL can occur, most often in the context of chronic myelogenous leukemia (CML), and two cases were submitted to this session. Case 17 was from a 64-year-old man with a 12-year history of chronic phase CML who then developed generalized lymphadenopathy. Lymph node biopsy specimen showed morphologic and immunophenotypic features typical of T-LBL. BCR-ABL1 p210 transcripts were demonstrated, and karyotyping showed a complex karyotype, including an additional t(9;22)(q34;q11.2) and trisomy 8 ❚Image 2❚.
Case 430 was from a 54-year-old woman who presented de novo with lymphadenopathy. Lymph node biopsy specimen showed T-LBL with a cortical thymocyte immunophenotype (CD1a+) and a monocytic population that was CD56 positive. The peripheral blood showed a marked leukocytosis (WBC count, 117 × 10 9 /L) with 39% lymphoblasts, monocytosis, and left-shifted neutrophilic leukocytosis. Flow cytometry immunophenotyping showed two cell populations: T cell and monocytic (CD4+, CD14+, CD36+, CD56+). BM examination showed hypercellular BM with lymphoblasts and monocytic and myeloid precursors. Conventional cytogenetics showed a t(9;22)(q34;q11.2) and an add(7)(q34). A p190 transcript was detected. The descriptive diagnosis of T-ALL, Ph+, p190 BCR-ABL1 variant with monocytosis vs blast phase CML was agreed upon by the review panel to reflect uncertainty as to whether chronic CML had been present but previously unrecognized in this patient. Ph+ or BCR-ABL1+ T-ALL is rare and represents less than 2% of all cases of T-ALL. 1, 2, 16 It is most easily recognized in the context of CML. True cases of de novo BCR-ABL1+ T-ALL are difficult (if not impossible) to distinguish from T-lymphoid blast phase of CML. Features that have been used to favor T-ALL include age younger than 18 years, no history of CML, p190 transcripts, and fluorescence in situ hybridization (FISH) studies showing the BCR-ABL1 fusion only in lymphoblasts. Features that support blast phase of CML include lack of BM involvement by T-ALL, solitary extramedullary involvement, and FISH studies showing the BCR-ABL1 fusion in both lymphoid and myeloid lineages. 16 
Do MYC Translocations Occur in T-ALL?
Two cases of blastic T-cell neoplasms associated with MYC translocation were submitted to this session. Case 408 was from an 8-year-old boy with fever, lymphadenopathy, and leukocytosis. Immunophenotyping showed a T-lymphoblast population (CD1a+) and karyotyping showed a t(7;9) (q?36;q34) suggesting a NOTCH1 translocation as well as t(8;14)(q24;q11.2). The patient relapsed 6 months after therapy with a more mature T-lymphoid population positive for CD3, CD8, and T-cell receptor (TCR) a/b (Vb13.1). Conventional cytogenetics showed a complex karyotype, but with the two translocations observed previously. The review panel agreed with the submitting diagnosis of T-ALL. This neoplasm was also shown to express PTK7, a protein tyrosine kinase involved in neural development and expressed in myeloid and precursor B blasts and thymic T cells but not in mature T cells. A recent study suggests PTK7 may be overexpressed in T-ALL compared with normal cells and that assessment of PTK7 might be a useful biomarker for the detection of minimal residual disease in patients with T-ALL. 17 Case 406 was from a 4-year-old girl with hepatosplenomegaly and marked leukocytosis of 731 × 10 9 /L with 86% blasts in the blood smear ❚Image 3❚. Flow cytometry immunophenotyping showed a mature T-cell immunophenotype with expression of surface CD3 and TCRg/d, and immunohistochemistry (IHC) showed expression of MYC and weak expression of the cytotoxic markers TIA-1, granzyme B, and perforin. Conventional cytogenetics showed 47,XX, t(8;14)(q24.1;q11.2),+17 [17] /46,idem,-9,i(9)(q10) [3] . MYC translocation was confirmed by FISH. TCRa/d resides at the chromosome 14q11 locus. The review panel thought the best diagnosis for this case was blastoid g/d T-cell lymphoma with a mature T-cell immunophenotype.
The simple answer to the question above is that MYC translocations can occur in T-ALL but only rarely, with very few unequivocal cases reported in the literature. 18, 19 Older case series lack detailed immunophenotypic data, and therefore the status of markers currently accepted as those of immature or precursor T cells is unknown. T-ALL associated with MYC translocations has been reported to follow an aggressive clinical course with poor response to therapy. 18 However, aggressive modern therapy with high-dose methotrexate and stem cell transplantation resulted in long-term remission in one patient reported. 19 Given the recent interest in using IHC to assist in identifying diffuse aggressive B-cell lymphoma, it is unclear whether a similar approach could be taken to screen for MYC translocations in T-ALL. However, in a study using a polyclonal antibody, most T-ALL cases were shown to express MYC. 20 
What Are Indolent T-Lymphoblastic Proliferations?
Case 223 was from a 56-year-old woman with a large 7.5-cm retroperitoneal mass discovered due to epigastric pain. Biopsy specimen revealed hyaline vascular Castleman disease. Due to the large size and location of the mass, chemotherapy and immunotherapy were administered to © American Society for Clinical Pathology facilitate surgical management. However, this approach resulted in only a modest reduction in the size of the mass. Surgical resection revealed lymphocyte-rich areas that, upon immunohistochemical characterization, were found to consist of T cells positive for CD4, CD8, CD1a, CD99, and TdT and had a high proliferation index (Ki-67 >90%) ❚Image 4❚. These cells were negative for B-cell markers, and there was no evidence of an epithelial component. TCR rearrangement studies were negative. Hyaline vascular Castleman disease was also present in the background. The panel agreed with the submitted diagnosis of an indolent T-lymphoblastic proliferation associated with hyaline vascular Castleman disease. Indolent T-lymphoblastic proliferations are benign proliferations of precursor T cells with a cortical thymocyte immunophenotype. Approximately 10 cases have been reported, and this topic was reviewed recently. 21 Indolent T-lymphoblastic proliferation is known to occur in association with Castleman disease, various types of carcinoma, follicular dendritic tumor, and angioimmunoblastic T-cell lymphoma. Indolent T-lymphoblastic proliferations can be recognized as a focal collection of T lymphoblasts with a cortical T-cell immunophenotype (CD4+CD8+CD1a+TdT+), as shown in this case. The cells are negative for CD34, and there is no evidence of a monoclonal T-cell population (by immunophenotyping or molecular methods). Importantly, the underlying architecture of the tissue is preserved, and there is no evidence of aberrant antigen expression. No thymic epithelium is found, distinguishing these lesions from thymoma. The clinical course is indolent, with no evidence of progression, and no specific treatment is needed. Awareness of this entity is required to prevent overtreatment.
How Does One Distinguish T-ALL/ T-LBL From Thymoma?
Case 373 was from a 45-year-old man with dyspnea, fatigue, and dry cough, and imaging studies showed a 12-cm mediastinal mass. A limited needle core biopsy specimen showed T cells with a cortical (CD1a+) immunophenotype. Flow cytometry of pleural fluid detected these CD1a+ T cells in a background of a mixed T-cell population of CD4+ or CD8+ T cells. Immunostaining showed some reactivity for cytokeratin, and a diagnosis of thymoma was thought most likely ❚Image 5❚. BM examination was negative for lymphoma/leukemia. After one cycle of chemotherapy for thymoma and review of the core biopsy material, the possibility of T-LBL was again entertained and resulted in a thoracoscopic biopsy specimen demonstrating similar findings to the original needle biopsy specimen. Keratin-positive cells were rare in this biopsy specimen, and immunostaining showed these cells to be calretinin+/WT1+/p63-, consistent with entrapped mesothelial cells. Furthermore, a T-cell clone was detected in pleural fluid by polymerase chain reaction, and karyotyping revealed the t(7;9)(q34;q34) likely involving NOTCH1. An unequivocal diagnosis of T-LBL was then established.
This case illustrates a diagnostic dilemma all too familiar to pathologists. In a patient with a mediastinal mass, the differential diagnosis of lymphocyte-rich thymoma vs T-lymphoblastic lymphoma can be challenging and made more so by having only limited material to evaluate. Immunohistochemical analysis to assess for the presence of keratin-positive cells and further characterization of these © American Society for Clinical Pathology cells with newer antibodies with more specificity (epithelial vs mesothelial cells) may be helpful. 22, 23 Flow cytometry immunophenotyping and molecular genetics can be helpful in differential diagnosis (Table 2) . Flow cytometric immunophenotypic features favoring T-LBL over thymoma include expression of CD10 and/or CD34, presence of a tight cluster of lymphoblasts, and absence of surface CD3, CD2, or CD5. 24 Assessment of T-cell clonality or the presence of characteristic cytogenetic or molecular abnormalities known to be associated with T-LBL, such as characteristic translocations, as in this case, or NOTCH1 mutation, also may assist in this differential diagnosis. Recently, commercial antibodies to NICD1 have become available and hold promise for demonstrating activation of the NOTCH1 pathway, a finding that would support a diagnosis of T-LBL over thymoma. 25, 26 Case 292 also illustrated the differential diagnosis of T-LBL vs thymoma. This highly unusual case was from a 72-year-old man who developed concurrent thymoma and T-LBL.
Can Lineage Switch Occur After Therapy for T-ALL/T-LBL?
Case 274 was from a 13-year-old boy who initially had B-type symptoms and a leukocyte count of around 300 × 10 9 /L ❚Image 6❚. The diagnosis of T-ALL associated with t(5;14)(q35;q32) was established, and appropriate aggressive chemotherapy was initiated. Six months later while receiving delayed-intensification therapy, the patient relapsed with acute myeloid leukemia. Despite a change in therapy, the patient went on to develop leukemia cutis and died within 2 months.
This case of bilineal acute leukemia with t(5;14) (q35;q32) involving TLX3 at 5q35 and BCL11B at 14q32 is highly unusual but illustrates that lineage switch can occur after therapy. FISH was able to show the cryptic translocation in the relapse specimen, supporting the lineage switch and excluding the possibility of a new therapy-related myeloid neoplasm. A similar case has been reported in the literature. 27 
Other Cases Submitted to the Session
Other cases submitted to this session were single examples of highly unusual diseases or clinical scenarios ❚Table 5❚, including acute myeloid leukemia arising in a patient following T-ALL and treatment (case 114), an atypical histiocytic proliferation with a juvenile xanthogranuloma phenotype in a patient with a history of T-ALL (case 124), a patient with T-ALL who responded to nelarabine (case 163), a case of T-ALL associated with a DNMT3A mutation (case 438), and a difficult-to-classify T-cell neoplasm associated with hemophagocytic lymphohistiocytosis (case 53).
Summary
This session highlighted the heterogeneity of T-lymphoblastic neoplasms. Through the application of molecular genetic tools, we are beginning to define the biologic pathways and genetic alterations that are involved in the pathogenesis of T-ALL/T-LBL, exemplified by cases with NOTCH1, TLX3, BCR-ABL1, and MYC abnormalities. GEP has led to the concept of ETP-ALL, a disease that is clinically important to recognize because patients with these tumors have a poor prognosis when treated with standard therapy. A consensus immunophenotype has been developed T-ALL (T-IV; surface CD3 positive) with DNMT3A mutation ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; Ph+, Philadelphia chromosome positive; T-ALL, T-acute lymphoblastic leukemia; TCR, T-cell receptor.
to aid in the recognition of ETP-ALL, and several cases in this session illustrated acceptable examples of these tumors. This session also touched on additional diagnostic issues important for pathologists, such as the existence of indolent T-lymphoblastic proliferations and the problem of distinguishing T-ALL/T-LBL from thymoma. In view of the complexity of T-lymphoblastic proliferations and growing importance of molecular genetic analysis in the diagnosis and prognosis of T-ALL/T-LBL, it is important for pathologists to keep abreast of these developments and adapt our daily practice. Currently, use of routine histopathology, flow cytometry immunophenotyping, conventional cytogenetic analysis, FISH, and clonality testing is usually adequate to establish the diagnosis. However, as therapies become more targeted, the need to assess for relevant genetic abnormalities, either through candidate gene or broad-scale unbiased approaches, may become necessary. 
